biotech · Chronic Hepatitis D Virus (HDV) Infection · Chronic Hepatitis B · VIR
Vir Biotechnology
Vir Biotechnology is a biotech organization headquartered in San Francisco, USA. It trades on NYSE under ticker VIR. Primary therapeutic focus areas include Chronic Hepatitis D Virus (HDV) Infection, Chronic Hepatitis B,
1800 Owens St, Suite 900, San Francisco, California 94158, US HQ
2016 Founded
479 Employees
Public company Type
VIR · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1800 Owens St, Suite 900, San Francisco, California 94158, US
- Founded
- 2016
- Employees
- 479
- Programs
- 34
- Drugs
- 17
- Patents
- 6
VIR-2218
Phase 1 · small molecule · Hepatic Impairment
VIR-2218 for Hepatic Impairment is a Phase 1 program (small_molecule) at Vir Biotechnology with 1 ClinicalTrials.gov record(s).
Internal code VIR-2218-V107
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Vir Biotechnology
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Hepatic Impairment
- Status
- active
- Trials
- 1